Chong Kun Dang Pharmaceutical Corp. - Product Pipeline Review - 2014

Published: Dec, 2014 | Pages: 56 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Chong Kun Dang Pharmaceutical Corp. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Chong Kun Dang Pharmaceutical Corp. - Product Pipeline Review - 2014', provides an overview of the Chong Kun Dang Pharmaceutical Corp.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Chong Kun Dang Pharmaceutical Corp.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Chong Kun Dang Pharmaceutical Corp. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Chong Kun Dang Pharmaceutical Corp.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Chong Kun Dang Pharmaceutical Corp.'s pipeline products

Reasons to buy

- Evaluate Chong Kun Dang Pharmaceutical Corp.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Chong Kun Dang Pharmaceutical Corp. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Chong Kun Dang Pharmaceutical Corp.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Chong Kun Dang Pharmaceutical Corp. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Chong Kun Dang Pharmaceutical Corp.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Chong Kun Dang Pharmaceutical Corp. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Chong Kun Dang Pharmaceutical Corp. Snapshot 6
Chong Kun Dang Pharmaceutical Corp. Overview 6
Key Information 6
Key Facts 6
Chong Kun Dang Pharmaceutical Corp. - Research and Development Overview 7
Key Therapeutic Areas 7
Chong Kun Dang Pharmaceutical Corp. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Chong Kun Dang Pharmaceutical Corp. - Pipeline Products Glance 15
Chong Kun Dang Pharmaceutical Corp. - Late Stage Pipeline Products 15
Phase III Products/Combination Treatment Modalities 15
Chong Kun Dang Pharmaceutical Corp. - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
Chong Kun Dang Pharmaceutical Corp. - Early Stage Pipeline Products 18
Preclinical Products/Combination Treatment Modalities 18
Chong Kun Dang Pharmaceutical Corp. - Drug Profiles 19
beloranib 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
carvedilol SR 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
CKD-943 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
(amlodipine besylate + candesartan) 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
CKD-941 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
CKD-942 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
CR-845 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
LT-0011 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
CKD-12101 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
CKD-12201 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
CKD-516 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
CKD-519 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
CKD-581 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
CKD-902 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
CKD-903 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
darbepoetin alfa 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
CKD-10101 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
CKD-830 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
CKD-841 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Drug to Inhibit HDAC6 for Rheumatoid Arthritis 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Nepodin 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Chong Kun Dang Pharmaceutical Corp. - Pipeline Analysis 43
Chong Kun Dang Pharmaceutical Corp. - Pipeline Products by Target 43
Chong Kun Dang Pharmaceutical Corp. - Pipeline Products by Route of Administration 45
Chong Kun Dang Pharmaceutical Corp. - Pipeline Products by Molecule Type 46
Chong Kun Dang Pharmaceutical Corp. - Pipeline Products by Mechanism of Action 47
Chong Kun Dang Pharmaceutical Corp. - Recent Pipeline Updates 48
Chong Kun Dang Pharmaceutical Corp. - Dormant Projects 53
Chong Kun Dang Pharmaceutical Corp. - Locations And Subsidiaries 54
Head Office 54
Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 55
Contact Us 56
Disclaimer 56

List of Tables
Chong Kun Dang Pharmaceutical Corp., Key Information 6
Chong Kun Dang Pharmaceutical Corp., Key Facts 6
Chong Kun Dang Pharmaceutical Corp. - Pipeline by Indication, 2014 9
Chong Kun Dang Pharmaceutical Corp. - Pipeline by Stage of Development, 2014 10
Chong Kun Dang Pharmaceutical Corp. - Monotherapy Products in Pipeline, 2014 11
Chong Kun Dang Pharmaceutical Corp. - Combination Treatment Modalities in Pipeline, 2014 12
Chong Kun Dang Pharmaceutical Corp. - Partnered Products in Pipeline, 2014 13
Chong Kun Dang Pharmaceutical Corp. - Partnered Products/ Combination Treatment Modalities, 2014 14
Chong Kun Dang Pharmaceutical Corp. - Phase III, 2014 15
Chong Kun Dang Pharmaceutical Corp. - Phase II, 2014 16
Chong Kun Dang Pharmaceutical Corp. - Phase I, 2014 17
Chong Kun Dang Pharmaceutical Corp. - Preclinical, 2014 18
Chong Kun Dang Pharmaceutical Corp. - Pipeline by Target, 2014 44
Chong Kun Dang Pharmaceutical Corp. - Pipeline by Route of Administration, 2014 45
Chong Kun Dang Pharmaceutical Corp. - Pipeline by Molecule Type, 2014 46
Chong Kun Dang Pharmaceutical Corp. - Pipeline Products by Mechanism of Action, 2014 47
Chong Kun Dang Pharmaceutical Corp. - Recent Pipeline Updates, 2014 48
Chong Kun Dang Pharmaceutical Corp. - Dormant Developmental Projects,2014 53